Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454972 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
A Phase 2 study of Advanced Solid Tumors, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 2
- Development phase
- 345
- Enrollment target
- 20
- Study locations
NCT02454972: Completed Phase 2 study of Advanced Solid Tumors, sponsored by PharmaMar.
NCT02454972 is a Phase 2 study of Advanced Solid Tumors that has completed, run by PharmaMar. The registered enrollment target is 345 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (76% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02454972, a Phase 2 study of Advanced Solid Tumors, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 345 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, open-label, exploratory, phase II clinical trial to evaluate the efficacy and safety of PM01183 in previously treated patients with advanced solid tumors
Primary Outcome
Overall Response Rate was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): ≥30% decrease in the sum of the longest diameters of target lesions compared with baseline; Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest; diameter recorded or the appearance of one or more new le
Conditions Studied
Interventions
- DRUG lurbinectedin (PM01183)
Study Locations (20)
Other
- Institut Jules Bordet - Brussels
- Hôpital Cochin - Paris
- Institut Claudius Regaud - Toulouse
- Institut Gustave Roussy - Villejuif
- Charité Universitätsmedizin Berlin - Campus Benjamin Franklin - Comprehensive Cancer Center - Berlin
- Charité - Universitätsmedizin Berlin - Berlin
- Istituto Ortopedico Rizzoli - Bologna
- lstituto Europeo di Oncologia - Milan
- ASST Monza - Ospedale San Gerardo di Monza Struttura Complessa di Oncologia Medica - Monza
- AUSL Romagna - Ospedale Santa Maria delle Croci - Ravenna
Massachusetts
- Massachussets General Hospital - Boston
- Beth Israel Deaconess Medical Centre - Boston
- Dana Farber Cancer Institute - Boston
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- Institute for Drug Development, Cancer Therapy & Research Center at University of Texas Health Science Center - San Antonio
California
- Sarcoma Oncology Research Center, LLC - Santa Monica
Colorado
- University of Colorado Cancer Center - Aurora
Milan
- Istituto Clinico Humanitas - Rozzano
A Coruña
- Complexo Hospitalario Universitario de Santiago - Santiago de Compostela
Guipúzcoa
- Hopsital Universitario Donostia - Donostia Unibertsitate Ospitalea - San Sebastián
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2015-08-25 |
| Est. Completion | 2020-09-18 |
| Phase | Phase 2 |
What the finished NCT02454972 record still lists
NCT02454972 is an interventional study that assigns participants to a tested intervention. The registered 345 participants enrollment target is mid-sized for trials with a published cap, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (76% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which lurbinectedin (PM01183) is the first listed.
NCT02454972 names 20 study sites across 8 states, led by Other, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT02454972 about?
NCT02454972 is a clinical study titled "Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors". Multicenter, open-label, exploratory, phase II clinical trial to evaluate the efficacy and safety of PM01183 in previously treated patients with advanced solid tumors
What is the current status of trial NCT02454972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2015-08-25. Estimated completion is 2020-09-18.
What conditions does trial NCT02454972 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT02454972?
The interventions under investigation include: lurbinectedin (PM01183) (DRUG).
Who is sponsoring clinical trial NCT02454972?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02454972 being conducted?
This trial has 20 study locations across California, Colorado, Massachusetts, Texas, Milan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02454972's enrollment target sits among peer trials
345 21st of 144 higher than 124 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
RECRUITING · Phase 2
-
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
RECRUITING · Phase 2
-
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RECRUITING · Phase 2
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NCT05107674 · 345 participants · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
- NCT05700279 · 345 participants · NA
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
- NCT05781100 · 345 participants · NA
Investigating Baby Behavior and Family Technology Use Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI